Genetic Technologies Limited (GTG.AX)
| Previous close | 0.0030 |
| Open | 0.0030 |
| Bid | 0.0030 x 10000000 |
| Ask | 0.0040 x 249000000 |
| Day's range | 0.0030 - 0.0030 |
| 52-week range | 0.0020 - 0.0080 |
| Volume | |
| Avg. volume | 13,924,844 |
| Market cap | 34.625M |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0000 |
| Earnings date | 27 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
GeneType Multi-Risk Test now includes Melanoma, Pancreatic Cancer & Atrial Fibrillation
MELBOURNE, Australia, March 27, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce the US launch of three (3) new diseases taking the total number of individual risk assessments included in the geneType Multi-Test to nine (9), all from the one simple saliva sample. This launch is in line with phase 2 rollout plan for the geneType Multi Risk-Test
- GlobeNewswire
Back-to-back Studies Validate geneType Breast Cancer Risk Test
MELBOURNE, Australia, March 13, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the publication of another research paper supporting the utilisation of geneType Breast Cancer Risk Assessment Test in the peer-reviewed journal Cancer Prevention Research. Highlights: 2nd published peer reviewed paper in the last month supporting the use of geneTyp
- GlobeNewswire
New Publication Highlights geneType’s Ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification
MELBOURNE, Australia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce the publication of a new research paper in the peer-reviewed journal Breast Cancer Research and Treatment. Highlights: GeneType outperforms 5-year and remaining lifetime risk prediction compared to the commonly used clinical models Gail and IBISv7, respectively.The
